-

Aditxt Webinar at 2pm ET to Explore PRESECO Results

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), has announced a webinar at 2pm ET this afternoon to discuss its earlier announcement today.

All investors are invited to attend, whether professional or individual.

On today’s webinar, CEO Amro Albanna will be sharing full information with all existing and potential investors. If you have questions, please submit them via email: aditxt@edisongroup.com.

To join the webinar, click here at 2pm. Or paste the link directly into your browser: https://us06web.zoom.us/j/82136059143

Contacts

Aditxt, Inc.
IR@aditxt.com

Media and Investor Relations Contact:
Edison Investment Research
aditxt@edisongroup.com

Aditxt, Inc.

NASDAQ:ADTX

Release Versions

Contacts

Aditxt, Inc.
IR@aditxt.com

Media and Investor Relations Contact:
Edison Investment Research
aditxt@edisongroup.com

More News From Aditxt, Inc.

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein...

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap...

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the r...
Back to Newsroom